Mountain Valley MD Holdings Inc.

MVMD

CA62430M1014

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 12:02:32 2024-04-22 pm EDT			5-day change	1st Jan Change
0.055 ^CAD	0.00%		0.00%	+37.50%

Mar. 01	Mountain Valley MD Holdings Inc. Plans to Introduce Soluvec 1% Coated Fish Feed in Bangladesh by May of 2024	CI
Mar. 01	Mountain Valley MD Holdings Inc. Provides Update on Agrarius Trial Results	CI

Mountain Valley MD Holdings Inc. Reports Earnings Results for the Full Year Ended March 31, 2022

July 13, 2022 at 01:09 pm EDT

Mountain Valley MD Holdings Inc. reported earnings results for the full year ended March 31, 2022. For the full year, the company reported sales was CAD 0.11 million. Net loss was CAD 9.71 million compared to CAD 8.14 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago.

Latest news about Mountain Valley MD Holdings Inc.

Mountain Valley MD Holdings Inc. Plans to Introduce Soluvec 1% Coated Fish Feed in Bangladesh by May of 2024	Mar. 01	CI
Mountain Valley MD Holdings Inc. Provides Update on Agrarius Trial Results	Mar. 01	CI
Mountain Valley MD Holdings Inc.?s Contracted Manufacturing Partner in the U.S. Completes the Set-Up and Testing of Equipment to Enable the Proprietary Production of Nutraceutical Applications for MVMD?s Quicksome Technology, Including Sublingual Rapid Dissolve Tablets and Powders	Mar. 01	CI
Mountain Valley MD Holdings Inc. Announces CFO Changes	Mar. 01	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
Mountain Valley Says Yong Yao to Take Role of CFO in January	Dec. 15	MT
Mountain Valley MD Holdings Inc. Announces CFO Changes Effective January 15, 2024	Dec. 15	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
Mountain Valley Appoints New CFO	23-09-08	MT
Mountain Valley MD Holdings Inc. Announces Chief Financial Officer Changes	23-09-07	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Mountain Valley MD Holdings Inc. Announces Publication of Soluvec Trial Data in Therapeutic Delivery	23-08-08	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-11	CI
Mountain Valley MD Holdings Inc. Enters into A License Agreement with Ontario Corporation for Its Soluvec™1% Animal Husbandry Applications for the Territory of the People's Republic of Bangladesh	23-05-08	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-27	CI
Mountain Valley MD Says Chief Medical Officer Transitioning to Advisory Role; Shares Down 15%	23-01-12	MT
Mountain Valley Md Holdings Inc. Announces Transition of Azhar Rana, Chief Medical Officer to Advisory Role	23-01-11	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-29	CI
Mountain Valley MD Holdings Inc. Commences Commercial Sales of Agrarius, an Agro Plant Technology	22-09-13	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-21	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-07-13	CI
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study for Soluvec™1%	22-06-27	CI
Mountain Valley MD Holdings Inc. Appoints Elizabeth Norton to Advisory Role	22-03-15	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-28	CI
Mountain Valley MD Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-28	CI

Chart Mountain Valley MD Holdings Inc.

Duration

Period

More charts

Company Profile

Mountain Valley MD Holdings Inc. is a Canada-based biotech company, which is focused on advancing solutions to optimize human, animal, and plant health. The Company is focused on implementation, licensing and reselling of key technologies and formulations, such as Quicksome oral formulation and delivery technologies, Quicksol solubility formulation technology, and Agrarius, a novel agricultural plant signaling technology. Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into efficient product formats. Quicksol technology covers all solubilized macrocyclic lactones that could be applied in multiple viral applications that could impact human and animal health globally. Agrairus agricultural plant signaling technology is used as application to agricultural crops to naturally increase yields, reduce fertilizer usage, and enhance general resilience to pests and climate change.

Sector

Pharmaceuticals

Calendar

2024-07-10 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
MOUNTAIN VALLEY MD HOLDINGS INC.	+37.50%	13.21M
DONG-E-E-JIAO CO.,LTD.	+39.54%	6.12B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.47%	4.44B
TASLY PHARMACEUTICAL GROUP CO., LTD	-10.16%	3.14B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.03B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.06%	2.57B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+40.09%	1.87B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.76%	1.63B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-11.19%	1.62B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.74%	1.53B